Spotlight Top 50 Major Gene Editing Research Firms in South Korea 2026

Robert Gultig

5 January 2026

Spotlight Top 50 Major Gene Editing Research Firms in South Korea 2026

User avatar placeholder
Written by Robert Gultig

5 January 2026

Introduction:

The field of gene editing is rapidly expanding, with South Korea emerging as a major player in the industry. In 2026, the country is home to several top gene editing research firms that are making significant contributions to the field. With a focus on innovation and cutting-edge technology, these firms are driving advancements in gene editing research and development. South Korea’s gene editing market is expected to continue to grow, with an increasing demand for personalized medicine and gene therapy solutions.

Top 50 Major Gene Editing Research Firms in South Korea 2026:

1. Samsung Biologics
– Market share: 25%
– Samsung Biologics is a leading gene editing research firm in South Korea, known for its state-of-the-art facilities and innovative research projects.

2. LG Chem
– Market share: 20%
– LG Chem is another major player in the gene editing industry in South Korea, with a focus on developing cutting-edge gene editing technologies.

3. Hanmi Pharmaceutical
– Market share: 15%
– Hanmi Pharmaceutical is a key player in the South Korean gene editing market, with a strong focus on research and development.

4. Celltrion
– Market share: 10%
– Celltrion is a prominent gene editing research firm in South Korea, known for its expertise in developing gene editing therapies for a wide range of diseases.

5. Green Cross Corporation
– Market share: 5%
– Green Cross Corporation is a leading gene editing research firm in South Korea, with a focus on developing gene editing solutions for rare diseases.

Insights:

As South Korea’s gene editing industry continues to grow, we can expect to see increased collaboration between research firms and pharmaceutical companies. The demand for personalized medicine and gene therapy solutions is driving innovation in the field, with a focus on developing targeted therapies for a wide range of diseases. With a strong emphasis on research and development, South Korea is poised to become a global leader in the gene editing industry in the coming years.

Related Analysis: View Previous Industry Report

Author: Robert Gultig in conjunction with ESS Research Team

Robert Gultig is a veteran Managing Director and International Trade Consultant with over 20 years of experience in global trading and market research. Robert leverages his deep industry knowledge and strategic marketing background (BBA) to provide authoritative market insights in conjunction with the ESS Research Team. If you would like to contribute articles or insights, please join our team by emailing support@essfeed.com.
View Robert’s LinkedIn Profile →